Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
D-Borneol is a naturally occurring bicyclic monoterpene and the dextrorotatory enantiomer of borneol. It is widely used in traditional Chinese medicine as an "orifice-opening" agent for resuscitative purposes and has been investigated for its ability to enhance drug delivery to the brain by transiently increasing blood–brain barrier (BBB) permeability[1][2][8]. D-Borneol acts as a central nervous system modulator with neuroprotective effects, including reducing glutamate levels, activating GABAA receptors, and blocking necrosis and apoptosis in ischemic stroke models[6][8]. Its mechanism involves downregulation of P-glycoprotein (P-gp), modulation of neurotransmitter levels such as serotonin (5-HT), and regulation of tight junction proteins at the BBB[6][8]. D-Borneol is also used as a flavoring agent and component in essential oils. It has been studied primarily as an adjuvant to improve CNS drug bioavailability rather than as a primary therapeutic agent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on d-borneol.